ClinicalTrials.gg
CompletedNCT06620419Updated Nov 19, 2026Results posted

Clinical Study of External Electrical Stimulation for Male Incontinence

An interventional study of Perineal-applied electrical stimulation in Urinary Incontinence, sponsored by Elidah, Inc.. Completed at 1 site in United States. Open to male participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Elidah, Inc. · Not applicable, Interventional, and Treatment

How we know

Updated Nov 19, 2026Now CompletedResults posted+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
37
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 293 studies in Urinary Incontinence with a site in United States — 33 open to participants now, 47 under way, 3 of them phase 3. Urinary Incontinence · United States.

Enrollment
165th of 249
37 · median 75
Started
2024
with 16 others
No phase
144 of 293
21 open now
Registered
270th of 293
by date

Among the 293 studies in Urinary Incontinence with a site in United States, this one is the 165th largest by enrollment of the 249 interventional ones that give a count, is one of 17 that started in 2024, is one of 144 with no phase, and was the 270th registered.

Urinary Incontinence

988 studies on the registry are indexed under Urinary Incontinence; 184 are open to participants now.

Browse Urinary Incontinence studies →

Open to participants now

33 of the 293 studies in Urinary Incontinence with a site in United States are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 113 Urinary Incontinence studies recruiting now, 63 (56%) set no upper age limit and 35 (31%) stop at 75 or younger; 15 take children under 18; 28 take healthy volunteers.

This study: 18 Years to 80 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 293 studies in Urinary Incontinence with a site in United States, or all of them as a file.
02

Study summary

The purpose of this research is to evaluate the effectiveness of the Elidah neuromuscular stimulation treatment to reduce incontinence in men post-prostatectomy.

03

Conditions studied

  • Urinary Incontinence

Browse trials for

Keywords

  • male
  • men
  • prostatetectomy
  • incontinence
  • electrical stimulation
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Scheduled for robotic-assisted laparoscopic prostatectomy
  • Read and speak English
  • Predominant SUI of at least 1 pad/day

Exclusion criteria

Exclusion Criteria:

  • History or symptoms of urinary incontinence, urinary retention, extra-urethral incontinence, overflow incontinence
  • Complete denervation of the pelvic floor
  • Severe Obesity as defined by >= 40
  • Has undergone pre-op pelvic floor exercise strengthening
  • Pelvic pain/painful bladder syndrome
  • Implanted cardiac device, untreated cardiac arrhythmia or suffer from other heart problems.
  • History of epilepsy
  • Underlying neurologic/neuromuscular disorder
  • Metal implants in the abdomen or pelvic area
  • Chronic coughing
  • Impaired decision making, suicidal thoughts, or drug/alcohol dependence
  • Uncontrolled intercurrent illness that would limit compliance with study requirements
  • Lacks capacity to adhere with study requirements
  • Lacks capacity to consent for themselves.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    Arm A: Scheduled for robotic assisted laparoscopic prostatectomy,

    Scheduled for robotic assisted laparoscopic prostatectomy.

    Device: Perineal-applied electrical stimulation

Interventions

  • DevicePerineal-applied electrical stimulation

    Small controller that outputs stimulation for stress incontinence and OAB, attached to a male-anatomy thin GelPad placed in the perineal area.

    Also known as: Elidah, Elitone, Edytone

06

What researchers measure

Primary outcomes

  1. 24-Hour Urine Leakage Measured by Pad Weight

    Urine leakage was assessed using a 24-hour pad weight test. Participants wore absorbent pads for 24 hours, after which the pads were collected and weighed to quantify urine leakage in grams. The reported values represent the mean absolute 24-hour pad weight at Week 6, not the change from baseline. Lower values indicate less urine leakage.

    Time frame: 6 weeks

  2. 24-Hour Urine Leakage Measured by Pad Weight

    Urine leakage was assessed using a 24-hour pad weight test. Participants wore absorbent pads for 24 hours, after which the pads were collected and weighed to quantify urine leakage in grams. The reported values represent the mean absolute 24-hour pad weight at Week 12, not the change from baseline. Lower values indicate less urine leakage.

    Time frame: 12 weeks

Secondary outcomes

  1. Number of Participants Without Adverse Events

    The number of participants who did not experience an adverse event during the 6-week assessment period. Adverse events were assessed as part of the study's safety evaluation.

    Time frame: 6 weeks

  2. Change in Incontinence Quality of Life (I-QOL) Score

    Urinary incontinence-related quality of life was assessed using the Incontinence Quality of Life (I-QOL) questionnaire. Each item is scored from 1 to 5. Item scores are summed and transformed to a total score ranging from 0 to 100, with higher scores indicating better quality of life. The reported outcome represents the change in total I-QOL score from baseline to Week 6, calculated as the Week 6 score minus the baseline score. Positive values indicate improved quality of life, while negative values indicate worsening quality of life. The possible change ranges from -100 to +100 points.

    Time frame: Baseline to 6 weeks

  3. Percentage Change in Daily Urinary Leakage Episodes

    Percentage reduction in the average number of urinary leakage episodes per day, including both stress and urge urinary incontinence episodes, from baseline to Week 6. Percentage reduction was calculated as \[(baseline episodes per day - Week 6 episodes per day) / baseline episodes per day\] × 100. Positive values indicate fewer leakage episodes, while negative values indicate an increase in leakage episodes.

    Time frame: Baseline to 6 weeks

  4. Percentage Change in Daily Urinary Leakage Episodes

    Percentage reduction in the average number of urinary leakage episodes per day, including both stress and urge urinary incontinence episodes, from baseline to Week 6. Percentage reduction was calculated as \[(baseline episodes per day - Week 6 episodes per day) / baseline episodes per day\] × 100. Positive values indicate fewer leakage episodes, while negative values indicate an increase in leakage episodes.

    Time frame: Baseline to 12 weeks

07

Results

Posted Nov 19, 2026

Participant flow

Participants were recruited throughout the U.S. through healthcare provider referrals and social media/online advertising directing candidates to a study website. Ads used terms related to incontinence, bladder leaks, prostate cancer surgery, and prostatectomy. Participant screening began in June 2024 and continued through November 2025. The first participant was enrolled on June 11, 2024.

Participant flow — Overall Study
MilestoneArm A
Started37
Completed17
Not completed20

Outcome measures

Primary24-Hour Urine Leakage Measured by Pad Weight

Urine leakage was assessed using a 24-hour pad weight test. Participants wore absorbent pads for 24 hours, after which the pads were collected and weighed to quantify urine leakage in grams. The reported values represent the mean absolute 24-hour pad weight at Week 6, not the change from baseline. Lower values indicate less urine leakage.

Time frame:
6 weeks
Reported as:
Mean · grams
24-Hour Urine Leakage Measured by Pad Weight
gramsArm A
24-Hour Urine Leakage Measured by Pad Weight199 ± 305
SecondaryNumber of Participants Without Adverse Events

The number of participants who did not experience an adverse event during the 6-week assessment period. Adverse events were assessed as part of the study's safety evaluation.

Time frame:
6 weeks
Reported as:
Count of participants · Participants
Number of Participants Without Adverse Events
ParticipantsArm A
Number of Participants Without Adverse Events17
SecondaryChange in Incontinence Quality of Life (I-QOL) Score

Urinary incontinence-related quality of life was assessed using the Incontinence Quality of Life (I-QOL) questionnaire. Each item is scored from 1 to 5. Item scores are summed and transformed to a total score ranging from 0 to 100, with higher scores indicating better quality of life. The reported outcome represents the change in total I-QOL score from baseline to Week 6, calculated as the Week 6 score minus the baseline score. Positive values indicate improved quality of life, while negative values indicate worsening quality of life. The possible change ranges from -100 to +100 points.

Time frame:
Baseline to 6 weeks
Reported as:
Mean · Scores on a Scale
Change in Incontinence Quality of Life (I-QOL) Score
Scores on a ScaleArm A
Change in Incontinence Quality of Life (I-QOL) Score25 ± 21.3
SecondaryPercentage Change in Daily Urinary Leakage Episodes

Percentage reduction in the average number of urinary leakage episodes per day, including both stress and urge urinary incontinence episodes, from baseline to Week 6. Percentage reduction was calculated as \[(baseline episodes per day - Week 6 episodes per day) / baseline episodes per day\] × 100. Positive values indicate fewer leakage episodes, while negative values indicate an increase in leakage episodes.

Time frame:
Baseline to 6 weeks
Reported as:
Mean · percent reduction
Percentage Change in Daily Urinary Leakage Episodes
percent reductionArm A
Percentage Change in Daily Urinary Leakage Episodes66.4 ± 25.7
SecondaryPercentage Change in Daily Urinary Leakage Episodes

Percentage reduction in the average number of urinary leakage episodes per day, including both stress and urge urinary incontinence episodes, from baseline to Week 6. Percentage reduction was calculated as \[(baseline episodes per day - Week 6 episodes per day) / baseline episodes per day\] × 100. Positive values indicate fewer leakage episodes, while negative values indicate an increase in leakage episodes.

Time frame:
Baseline to 12 weeks
Reported as:
Mean · percent reduction
Percentage Change in Daily Urinary Leakage Episodes
percent reductionArm A
Percentage Change in Daily Urinary Leakage Episodes87 ± 16.8
Primary24-Hour Urine Leakage Measured by Pad Weight

Urine leakage was assessed using a 24-hour pad weight test. Participants wore absorbent pads for 24 hours, after which the pads were collected and weighed to quantify urine leakage in grams. The reported values represent the mean absolute 24-hour pad weight at Week 12, not the change from baseline. Lower values indicate less urine leakage.

Time frame:
12 weeks
Reported as:
Mean · grams
24-Hour Urine Leakage Measured by Pad Weight
gramsArm A
24-Hour Urine Leakage Measured by Pad Weight32.7 ± 47.3

Adverse events

Collected over From Enrollment until the end, up to 12 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A0/17 (0%)0/17 (0%)0/17 (0%)

Baseline characteristics

Thirty-seven participants enrolled and met eligibility criteria. Seventeen completed the study and were included in the final analysis. The remaining participants did not complete the study because of dropout or incomplete treatment and/or follow-up assessments.

Age, Categorical
Age, Categorical(Participants)Arm A
<=18 years0
Between 18 and 65 years17
>=65 years20
Sex: Female, Male
Sex: Female, Male(Participants)Arm A
Female0
Male37
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Arm A
24-Hour Pad Weight
24-Hour Pad Weight(grams)Arm A
Mean609 ± 572
08

Study locations

1 site
  • Elidah
    Monroe, Connecticut 06468, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Jan 2026, 19 months.

Results were first posted in Nov 2026, 9 months after primary completion.

Of 63 industry-sponsored interventional studies with no phase under Urinary Incontinence, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 19. This study's 19 months is above that.

Counting every sponsor, half of 366 studies reached it within 15 months; a quarter within 7 and three quarters within 34.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: start May 2024 → Jun 2024, primary completion Jun 2026 → Jan 2026 and completion Jun 2026 → Feb 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2024
First posted
Oct 1, 2024
StartActual
Jun 11, 2024was May 2024
Primary completionActual
Jan 30, 2026was Jun 2026
CompletionActual
Feb 28, 2026was Jun 2026
Results first posted
Nov 19, 2026
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 19, 2026
Results
Results posted
posted Nov 19, 2026
Start date
May 15, 2024→Jun 11, 2024
Nov 19, 2026
Primary completion
Jun 30, 2026→Jan 30, 2026 (actual)
Nov 19, 2026
Study completion
Jun 30, 2026→Feb 28, 2026 (actual)
Nov 19, 2026
Enrollment
30 (estimated)→37 (actual)
Nov 19, 2026
Interventions
Arm changed Treatment group→Arm A: Scheduled for robotic assisted laparoscopic prostatectomy,
Nov 19, 2026
Primary outcomes
1 edited, 1 added
What changed in the outcomes
  • EditedReduction in24-Hour Urine Leakage Measured by Pad weightWeightTime frame: 6 weeks
  • Added24-Hour Urine Leakage Measured by Pad WeightTime frame: 12 weeks
Nov 19, 2026
Documents
Secondary outcomes
4 added, 6 removed
What changed in the outcomes
  • AddedNumber of Participants Without Adverse EventsTime frame: 6 weeks
  • AddedChange in Incontinence Quality of Life (I-QOL) ScoreTime frame: Baseline to 6 weeks
  • AddedPercentage Change in Daily Urinary Leakage EpisodesTime frame: Baseline to 6 weeks
  • AddedPercentage Change in Daily Urinary Leakage EpisodesTime frame: Baseline to 12 weeks
  • RemovedSafety measured by no Adverse eventsTime frame: 6 weeks
  • RemovedQuality of Life ImprovementTime frame: 6 weeks
  • RemovedQuality of Life ImprovementTime frame: 6 weeks
  • RemovedReduction in leakageTime frame: 6 weeks
  • RemovedReduction in leakage at NightTime frame: 6 weeks
  • RemovedReduction in leakageTime frame: 6 weeks
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Active, not recruiting→Completed
    Results posted
    Start date May 15, 2024→Jun 11, 2024
    Primary completion Jun 30, 2026→Jan 30, 2026 (now actual)
    Study completion Jun 30, 2026→Feb 28, 2026 (now actual)
    Enrollment 30 (estimated)→37 (actual)
    Primary outcomes 1 edited, 1 added
    What changed in the outcomes
    • EditedReduction in24-Hour Urine Leakage Measured by Pad weightWeightTime frame: 6 weeks
    • Added24-Hour Urine Leakage Measured by Pad WeightTime frame: 12 weeks
    Secondary outcomes 4 added, 6 removed
    What changed in the outcomes
    • AddedNumber of Participants Without Adverse EventsTime frame: 6 weeks
    • AddedChange in Incontinence Quality of Life (I-QOL) ScoreTime frame: Baseline to 6 weeks
    • AddedPercentage Change in Daily Urinary Leakage EpisodesTime frame: Baseline to 6 weeks
    • AddedPercentage Change in Daily Urinary Leakage EpisodesTime frame: Baseline to 12 weeks
    • RemovedSafety measured by no Adverse eventsTime frame: 6 weeks
    • RemovedQuality of Life ImprovementTime frame: 6 weeks
    • RemovedQuality of Life ImprovementTime frame: 6 weeks
    • RemovedReduction in leakageTime frame: 6 weeks
    • RemovedReduction in leakage at NightTime frame: 6 weeks
    • RemovedReduction in leakageTime frame: 6 weeks
    Interventions Arm changed Treatment group→Arm A: Scheduled for robotic assisted laparoscopic prostatectomy,
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06620419
Lead sponsor
Elidah, Inc.
Responsible party
Sponsor
First posted
Oct 1, 2024
Start date
Jun 11, 2024
Primary completion
Jan 30, 2026
Completion
Feb 28, 2026
Results posted
Nov 19, 2026
Last update
Nov 19, 2026

Study contacts

Gloria Kolb, MS,MBA
principal investigator · Elidah, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion